ClinicalTrials.gg
CompletedNCT04068896Updated May 29, 2025Results posted

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

A Phase 1/2 interventional study of NGM120 30mg and NGM120 100mg in Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer and Bladder Cancer, sponsored by NGM Biopharmaceuticals, Inc. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-29.

Sponsored by NGM Biopharmaceuticals, Inc · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,851 studies in Pancreatic Neoplasms with a site in United States — 298 open to participants now, 471 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
374th of 1,574
89 · median 37
Started
2019
with 93 others
Phase 1/2
222 of 1,851
42 open now
Registered
1,270th of 1,851
by date

Among the 1,851 studies in Pancreatic Neoplasms with a site in United States, this one is the 374th largest by enrollment of the 1,574 interventional ones that give a count, is one of 94 that started in 2019, is one of 222 in phase 1/2, and was the 1,270th registered.

Pancreatic Neoplasms

3,902 studies on the registry are indexed under Pancreatic Neoplasms; 1,004 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

298 of the 1,851 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

293 more — sign in →

All 298 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 741 Pancreatic Neoplasms studies recruiting now, 475 (64%) set no upper age limit and 152 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,851 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).

Read the detailed description

The aim of the study is to evaluate the safety and tolerability of NGM120 monotherapy in subjects with select advanced solid tumors (Part 1), NGM120 in combination with gemcitabine and Abraxane for the management of metastatic pancreatic cancer (Part 2), and NGM120 in metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed under 1 or more lines of ADT (Part 3), for up to 24 months of treatment.

03

Conditions studied

  • Pancreatic Cancer
  • Metastatic Castration-resistant Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Non-small Cell Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Ovarian Cancer
  • Head Neck Squamous Cell Carcinoma
  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (Part 1 and 2):

  1. Have confirmed pancreatic adenocarcinoma. Recurrent unresectable pancreatic cancer is acceptable as long as the treatment is .
  2. Have not received any approved chemotherapy, except in the setting.
  3. of at least 12 weeks
  4. Male subjects must agree to use as per protocol during the treatment period and for at least 90 days after the last study treatment administration and refrain from donating sperm during this period.
  5. Provision of an (within 5 years). If an archival sample is unavailable, a fresh biopsy can be obtained during Screening. If archival tissue or biopsy sample is unavailable, the subject is ineligible.

Inclusion Criteria (Part 3 Prostate Cancer):

  1. Metastatic, castrate resistance, histologically confirmed prostate cancer; continuous medical castration for ≥8 weeks prior to screening.
  2. Effective castration with serum testosterone levels \<0.5 ng/mL (50 ng/dL; 1.7 nmol/L).
  3. Have serum GDF15 levels ≥1300 pg/mL.
  4. Have experienced PSA progression under 1 or more lines of ADT in the absence or presence of radiographic and/or clinical progression, who decline or are not eligible to receive chemotherapy.
  5. Have had PSA doubling time of >3 months.

Exclusion Criteria (All parts):

  1. Subject was using medications within 14 days before Screening with the exception of topical (intranasal, inhaled, and local injection), systemic (prednisone equivalent 10 mg/day or less), or as needed for reactions such as computed tomography (CT) scan premedication.
  2. Subject has active infections or other serious underlying significant medical illness, abnormal and laboratory findings or psychiatric illness/social situation.
  3. Subject is using a pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implants, cochlear implants, or other electronic medical equipment.
  4. Subject has documented immunodeficiency or organ transplant.
  5. Subject has an untreated central nervous system disease, or cord compression.
  6. Subject has a history, or presence, of significant cardiovascular diseases; including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months before randomization, congestive heart failure > Class II, severe peripheral vascular disease, (QTc) prolongation >470 msec, clinically significant pericardial effusion.
  7. Subject has a history or presence of documented inflammatory bowel disease.
  8. Subject is known to be positive for (HIV) infection.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Part 1 NGM120 30mg

    NGM120 30mg Subcutaneous Injection

    Biological: NGM120 30mg

  • Experimental
    Part 1 NGM120 100mg

    NGM120 100mg Subcutaneous Injection

    Biological: NGM120 100mg

  • Experimental
    Part 2 NGM120 30mg

    NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

    Biological: NGM120 30mg with Gemcitabine and Abraxane

  • Experimental
    Part 2 NGM120 100mg

    NGM120 100mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

    Biological: NGM120 100mg with Gemcitabine and Abraxane

  • Experimental
    Part 3 NGM120 100mg Q3W

    NGM120 100mg Subcutaneous Injection NGM120 100mg Subcutaneous Injection every 3 weeks

    Biological: NGM120 100mg Q3W

  • Placebo comparator
    Part 2 Placebo

    Placebo together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

    Other: Placebo

Interventions

  • BiologicalNGM120 30mg

    NGM120 30mg Subcutaneous Injection

  • BiologicalNGM120 100mg

    NGM120 100mg Subcutaneous Injection

  • BiologicalNGM120 30mg with Gemcitabine and Abraxane

    Drug page: Anti-GFRAL Monoclonal Antibody NGM120

    NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

  • BiologicalNGM120 100mg with Gemcitabine and Abraxane

    Drug page: Anti-GFRAL Monoclonal Antibody NGM120

    NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

  • NGM120 100mg Subcutaneous Injection every 3 weeks

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. To Determine the Safety and Tolerability of NGM120 in Subjects

    Number of Participants with NGM120/Placebo-Related Treatment Emergent Adverse Events

    Time frame: From enrollment to end of treatment up to 24 months

  2. To Determine the Safety and Tolerability of NGM120

    Discontinuation of investigational product due to toxicity

    Time frame: From enrollment to end of treatment up to 24 months

  3. To Determine the Safety and Tolerability of NGM120

    Local injection-site symptom assessment as evidenced by incidence of injection-site reactions

    Time frame: From enrollment to end of treatment up to 24 months

07

Results

Posted May 29, 2025

Participant flow

89 patients were enrolled (signed consent), however only 87 patients received at least 1 dose of study treatment. The participant flow contains information from these 87 treated patients, that are also considered the Safety Analysis set for CSR and study results

Participant flow — Overall Study
MilestonePart 1 NGM120 30 mgPart 1 NGM120 100 mgPart 2 NGM120 30 mgPart 2 NGM120 100 mgPart 2 PlaceboPart 3 NGM120 100 mg
Started10101031206
Completed012400
Not completed109827206
Withdrew: Adverse event201000
Withdrew: Death31319170
Withdrew: Physician decision000100
Withdrew: Progressive disease353212
Withdrew: Study terminated by sponsor001214
Withdrew: Protocol violation000100
Withdrew: Withdrawal by subject030210
Withdrew: Symptomatic deterioration200000

Outcome measures

PrimaryTo Determine the Safety and Tolerability of NGM120 in Subjects

Number of Participants with NGM120/Placebo-Related Treatment Emergent Adverse Events

Time frame:
From enrollment to end of treatment up to 24 months
Reported as:
Count of participants · Participants
To Determine the Safety and Tolerability of NGM120 in Subjects
ParticipantsPart 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mg
To Determine the Safety and Tolerability of NGM120 in Subjects16617122
PrimaryTo Determine the Safety and Tolerability of NGM120

Discontinuation of investigational product due to toxicity

Time frame:
From enrollment to end of treatment up to 24 months
Reported as:
Count of participants · Participants
To Determine the Safety and Tolerability of NGM120
ParticipantsPart 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mg
To Determine the Safety and Tolerability of NGM120202830
PrimaryTo Determine the Safety and Tolerability of NGM120

Local injection-site symptom assessment as evidenced by incidence of injection-site reactions

Time frame:
From enrollment to end of treatment up to 24 months
Reported as:
Count of participants · Participants
To Determine the Safety and Tolerability of NGM120
ParticipantsPart 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mg
To Determine the Safety and Tolerability of NGM120010400

Adverse events

Collected over 3 years, 8 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 NGM120 30mg3/10 (30%)5/10 (50%)10/10 (100%)
Part 1 NGM120 100mg1/10 (10%)3/10 (30%)10/10 (100%)
Part 2 NGM120 30mg3/10 (30%)5/10 (50%)10/10 (100%)
Part 2 NGM120 100mg19/31 (61.3%)26/31 (83.9%)31/31 (100%)
Part 2 Placebo17/20 (85%)10/20 (50%)20/20 (100%)
Part 3 NGM120 100mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventPart 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mg
SepsisInfections and infestations2/101/101/103/311/200/6
DiarrhoeaGastrointestinal disorders0/100/102/100/310/200/6
AnaemiaBlood and lymphatic system disorders0/100/100/101/311/201/6
Fibula fractureInjury, poisoning and procedural complications0/100/100/100/310/201/6
Tibia fractureInjury, poisoning and procedural complications0/100/100/100/310/201/6
SinusitisInfections and infestations0/100/101/100/310/200/6
Abdominal PainGastrointestinal disorders1/100/100/100/310/200/6
Rectal haemorrhageGastrointestinal disorders1/100/100/100/310/200/6
ColitisGastrointestinal disorders0/100/101/102/311/200/6
Abdominal PainGastrointestinal disorders0/100/100/101/312/200/6
Most frequent other events
Showing 10 of 194
Most frequent other events
EventPart 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mg
AlopeciaSkin and subcutaneous tissue disorders0/100/108/106/316/200/6
FatigueGeneral disorders4/102/107/1022/3111/200/6
DiarrhoeaGastrointestinal disorders2/101/107/1015/318/201/6
NauseaGastrointestinal disorders2/102/107/1013/318/200/6
Oedema peripheralGeneral disorders2/102/107/1013/317/202/6
PyrexiaGeneral disorders0/103/106/1014/314/200/6
AnaemiaBlood and lymphatic system disorders3/102/105/1016/3111/202/6
Neutrophil count decreasedInvestigations0/101/105/1013/319/200/6
Weight decreasedInvestigations2/101/105/1010/316/200/6
HeadacheNervous system disorders1/102/105/106/312/200/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mgTotal
<=18 years0000000
Between 18 and 65 years722114127
>=65 years3882016560
Age, Continuous
Age, Continuous(years)Part 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mgTotal
Mean58.8 ± 9.0865.6 ± 12.2167.7 ± 8.2767.0 ± 9.0669.9 ± 8.1069.0 ± 11.9267.2 ± 8.78
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mgTotal
Female4181311037
Male692189650
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mgTotal
Hispanic or Latino2120117
Not Hispanic or Latino8973015473
Unknown or Not Reported0011417
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mgTotal
American Indian or Alaska Native0000000
Asian1002104
Native Hawaiian or Other Pacific Islander0001203
Black or African American0214018
White8841711553
More than one race0000000
Unknown or Not Reported10576019
BMI
BMI(kg/m2)Part 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mgTotal
Mean24.93 ± 5.75926.46 ± 4.63626.53 ± 9.69425.72 ± 5.11925.04 ± 5.11331.20 ± 5.85226.03 ± 5.89
Metastatic Disease
Metastatic Disease(Participants)Part 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mgTotal
Yes910102919683
No1002104
Sites of Metastases
Sites of Metastases(count of metastatic sites)Part 1 NGM120 30mgPart 1 NGM120 100mgPart 2 NGM120 30mgPart 2 NGM120 100mgPart 2 PlaceboPart 3 NGM120 100mgTotal
Bone36110516
Liver5451716047
Lung244105126
Peritoneum2022006
Other22153215

1 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • NGM Clinical Study Site
    Tucson, Arizona 85719, United States
  • NGM Clinical Study Site
    Los Angeles, California 90048, United States
  • NGM Clinical Study Site
    Los Angeles, California 90084, United States
  • NGM Clinical Study Site
    Sacramento, California 98517, United States
  • NGM Clinical Study Site
    San Diego, California 92123, United States
  • NGM Clinical Study Site
    Santa Monica, California 90404, United States
  • NGM Clinical Study Site
    Aurora, Colorado 80045, United States
  • NGM Clinical Study Site
    Washington, District of Columbia 20007, United States
  • NGM Clinical Study Site
    Miami, Florida 33136, United States
  • NGM Clinical Study Site
    Chicago, Illinois 60611, United States
  • NGM Clinical Study Site
    Baltimore, Maryland 21201, United States
  • NGM Clinical Study Site
    Cincinnati, Ohio 45219, United States
  • NGM Clinical Study Site
    Philadelphia, Pennsylvania 19111, United States
  • NGM Clinical Study Site
    Charleston, South Carolina 29425, United States
  • NGM Clinical Study Site
    Myrtle Beach, South Carolina 29572, United States
  • NGM Clinical Study Site
    Nashville, Tennessee 37203, United States
  • NGM Clinical Study Site
    Dallas, Texas 75390, United States
  • NGM Clinical Study Site
    Houston, Texas 77030, United States
  • NGM Clinical Study Site
    Seattle, Washington 98101, United States
  • NGM Clinical Study Site
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Sep 2023, 47 months.

Results were first posted in May 2025, 1 year 8 months after primary completion.

Of 114 industry-sponsored phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's 47 months is close to that.

Counting every sponsor, half of 208 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2019
First posted
Aug 28, 2019
StartActual
Oct 16, 2019
Primary completionActual
Sep 21, 2023
CompletionActual
Jan 8, 2024
Results first posted
May 29, 2025
Last update
May 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04068896
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Oct 16, 2019
Primary completion
Sep 21, 2023
Completion
Jan 8, 2024
Results posted
May 29, 2025
Last update
May 29, 2025

Study contacts

NGM Study Director
study director · NGM Biopharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-GFRAL Monoclonal Antibody NGM120

Start the discussion